Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 12/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6395194 | 0.81 | OPRL1 (0.54) | OPRL1SIGMAR1OPRM1SLC18A3 | |
| SCHEMBL6394179 | 0.81 | OPRL1 (0.54) | OPRL1SIGMAR1OPRM1SLC18A3 | |
| Hydrochloric Acid SCHEMBL7070297 | 0.80 | OPRL1 (0.53) | OPRL1SIGMAR1OPRM1SLC18A3 | |
| SCHEMBL6396533 | 0.79 | DRD2 (0.50) | OPRL1SIGMAR1OPRM1SLC18A3 | |
| SCHEMBL6396536 | 0.79 | DRD2 (0.50) | OPRL1SIGMAR1OPRM1SLC18A3 | |
| Citric Acid SCHEMBL6394947 | 0.79 | OPRL1 (0.45) | OPRL1SIGMAR1OPRK1OPRM1SLC18A3 | |
| Hydrochloric Acid SCHEMBL6395171 | 0.79 | DRD2 (0.49) | OPRL1SIGMAR1OPRM1SLC18A3 | |
| Hydrochloric Acid SCHEMBL6395143 | 0.79 | DRD2 (0.49) | OPRL1SIGMAR1OPRM1SLC18A3 | |
| SCHEMBL6394941 | 0.78 | OPRL1 (0.50) | OPRL1SIGMAR1OPRM1SLC18A3 | |
| SCHEMBL6395355 | 0.78 | OPRL1 (0.50) | OPRL1SIGMAR1OPRM1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057222-B2 | COMPOSITION COMPRISING LIQUID PHOSPHITE BLENDS AS STABILIZERS | ADDIVANT SWITZERLAND GMBH (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-6919389-B2 | Polymer compositions containing benzimidazole based stabilizer compounds | CROMPTON CORPORATION (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050038060-A1 | Spiropoperidine compounds as ligands for orl-1 receptor | ANDO KOJI (JP) | 2005-02-17 | — | — | US | disclosed |
| US-20040180995-A1 | Polymer compositions containing benzimidazole based stabilizer compounds | ADDIVANT USA, LLC | 2004-09-16 | — | — | US | disclosed |
| EP-1399432-A1 | SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003000677-A1 | SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER PHARMACEUTICALS INC. (JP) | 2003-01-03 | — | — | WO | disclosed |
| US-6214915-B1 | AROMATIC KETONE STABILIZER | GENERAL ELECTRIC COMPANY | 2001-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038060-A1 | Spiropoperidine compounds as ligands for orl-1 receptor | OPRL1, OXER1, OGFRL1 | OPRL1 1/4885SIGMAR1 11/4885OPRK1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.